Dec. 4 at 4:36 PM
$MIST Deepseek:
Conclusion
The path to approval for CARDAMYST looks highly promising. The FDA's concerns were narrow, technical, and addressed. The clinical foundation is solid. While there is always regulatory risk until the official decision is received, the combination of factors suggests Milestone is in a strong position to secure approval on December 13, 2025. The significant increase in commercial expenses indicates management is operating with a high degree of conviction in this outcome..
